Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer.

Autor: Chen J; Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China., Yuan CB; Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China., Yang B; Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China., Zhou X; Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China.; Department of Intensive Care Medicine, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Jazyk: angličtina
Zdroj: Journal of oncology [J Oncol] 2021 Nov 25; Vol. 2021, pp. 4391581. Date of Electronic Publication: 2021 Nov 25 (Print Publication: 2021).
DOI: 10.1155/2021/4391581
Abstrakt: Background: Baicalin is a naturally occurring compound with anticancer, antioxidant, and anti-inflammatory properties. However, the mechanism underlying its anticancer activity on nonsmall cell lung cancer (NSCLC) remains unclear.
Methods: The effects of baicalin on the progression and metastasis of experimental NSCLC cell lines were studied in vitro and in vivo . Wound-healing and transwell assays were performed to evaluate the potency of baicalin and the motility and migration ability of NCI-H460 cells. Immunofluorescence assay, western blot assay, and immunohistochemistry test were conducted to investigate the inhibiting effect of baicalin on the epithelial-mesenchymal transition (EMT) of NSCLC.
Results: Baicalin inhibited the proliferation and migration of NCI-H446 human NSCLC cells in a dose-dependent manner, reduced the expression levels of phospho-3-phosphoinositide-dependent protein kinase 1 (p-PDK1) and phosphor-serine/threonine-protein kinase (p-AKT), reversed the levels of EMT markers, and inhibited the migration of NSCLC cells.
Conclusions: Baicalin impedes EMT by inhibiting the PDK1/AKT pathway in human NSCLC and thus may be an effective alternative treatment for carcinoma and a new candidate antimetastasis drug.
Competing Interests: The authors declare no conflicts of interest.
(Copyright © 2021 Jia Chen et al.)
Databáze: MEDLINE
Externí odkaz: